Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

BMS-986458 features three stereocenters, one of which epimerizes easily, Mortensen said. The drug candidate, which would be ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...

Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...

This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated ...

Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and ...